

Review

Open Access

Prevention of an additional surgery for regional lymphadenectomy in melanoma: rapid intraoperative immunostaining of sentinel lymph node imprint smears

Vinod B Shidham*¹, Richard Komorowski¹, Marcelle Neuberg², Alonzo Walker³, Bruce H Campbell⁴, Chung-Che Chang⁵ and William W Dzwierzynski⁶

Address: ¹Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA, ²Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA, ³Department of Otolaryngology, Medical College of Wisconsin, Milwaukee, WI, USA, ⁴Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA, ⁵Department of Pathology, The Methodist Hospital, Houston, TX, USA and ⁶Department of Plastic Surgery, Medical College of Wisconsin, Milwaukee, WI, USA

Email: Vinod B Shidham* - vshidham@mcw.edu; Richard Komorowski - rkomor@mcw.edu; Marcelle Neuberg - mneuberg@mcw.edu; Alonzo Walker - awalker@mcw.edu; Bruce H Campbell - bcampbel@mcw.edu; Chung-Che Chang - jeffchang@pol.net; William W Dzwierzynski - billd@mcw.edu

* Corresponding author

Published: 25 September 2006

Received: 13 September 2006

Diagnostic Pathology 2006, 1:32 doi:10.1186/1746-1596-1-32

Accepted: 25 September 2006

This article is available from: <http://www.diagnosticpathology.org/content/1/1/32>

© 2006 Shidham et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Sentinel lymph node (SLN) biopsy is performed at many institutions and is considered a standard of care in the management of cutaneous melanoma. The discriminatory immunostaining pattern with the 'MCW Melanoma Cocktail' (a mixture of MART-1 {1:500}, Melan-A {1:100}, and Tyrosinase {1:50} monoclonal antibodies) allows intraoperative immunocytochemical evaluation of imprint smears of SLNs for melanoma metastases. Cohesive cells of benign capsular melanocytic nevi that were also immunoreactive with the cocktail do not exfoliate easily for imprint smear detection.

Methods: We prospectively evaluated 73 lymph nodes (70 SLN & 3 non-SLN) from 41 cases (mean 1.8, 1 to 4 SLNs/case) of cutaneous melanoma using a rapid 17-minute immunostaining previously published protocol. The results were compared with permanent sections also immunostained with 'the cocktail'.

Results: 19.5%, 8/41 cases (12%, 9/73 lymph nodes) were positive for melanoma metastases on permanent sections immunostained with the 'MCW melanoma cocktail'. Melanoma metastases in 87.5% (7/8) of these cases were also detected in rapidly immunostained imprint smears, with 100% specificity and 90% sensitivity. None of the 7 SLNs from 7 cases with capsular nevi showed false positive results.

Conclusion: Melanoma metastases could be detected in imprint smears immunostained with 'MCW Melanoma Cocktail' utilizing a rapid intraoperative protocol. The cohesive cells of the capsular nevi do not readily exfoliate and do not lead to false positive interpretation. In a majority of positive cases, a regional lymphadenectomy could have been completed during the same surgery for SLN biopsy and wide excision of primary melanoma site, potentially eliminating the need for an additional surgery.

Background

Skin melanoma is the sixth most common cancer in US with an increasing rate in men [1]. Due to rapidly progressive nature of the disease, aggressive definitive therapy at earliest stage is the best option. Because of associated high morbidity and the scarcity of follow up studies evaluating its survival benefits, the role of routine performance of regional lymphadenectomy in all cases irrespective of their status is controversial [2,3]. An international multi-centre randomized prospective trial by the Intergroup Melanoma Surgical Program, reported that regional node dissection offers increased survival in subset of patients with nodal metastases (60 years of age or younger with intermediate-thickness nonulcerative melanomas) [4]. Sentinel lymph node (SLN) biopsy is recommended as a tool to identify this subset of patients, who could then undergo elective regional lymph node dissection [5]. The negative status of SLN for melanoma metastases correlates closely with the negative status of regional lymph nodes [6].

Thus, prevailing evidence supports the evaluation of SLN for melanoma metastases as the standard of care to identify subset of patients with metastases in cutaneous melanoma. It is practiced throughout the academic centers as well as regional and community hospitals with increasing frequency [2-22].

Although, it is beneficial to complete a regional lymphadenectomy during the same initial surgical procedure for 'SLN biopsy with wide excision of primary melanoma', currently the patient has to undergo regional lymphadenectomy at later date under separate anesthesia, if SLNs are positive for melanoma metastases. In the current situation the results can not be obtained intraoperatively. Preoperative or intraoperative evaluation technique would result in a cost saving with numerous other benefits [23-31].

Frozen-section examination (with or without immunohistochemical evaluation) and the morphological evaluation of imprint cytology smears are some of the methods evaluated for the intraoperative examination of SLN in cutaneous melanoma. However, the studies evaluating these methods did not demonstrate encouraging results [25-31], primarily due to lack of adequate sensitivity.

The 'MCW Melanoma Cocktail' (a mixture of MART-1 {1:500}, Melan-A {1:100}, and Tyrosinase {1:50} monoclonal antibodies) demonstrated an excellent discriminatory immunostaining pattern [32,33]. This has facilitated rapid intraoperative evaluation of SLNs for melanoma micrometastases by examining imprint smears of SLNs immunostained with the cocktail [34,35]. This was not previously possible with conventional immu-

nomarkers such as the S-100 protein and HMB45 due to significant interference caused by non-melanoma cells such as dendritic cells and mast cells resulting in a high noise to signal ratio [33,36].

In this article we report the results on a series of cutaneous melanoma cases studied with rapid intraoperative evaluation of SLN for melanoma metastases employing imprint smears immunostained with 'MCW melanoma cocktail'.

Materials and methods

Patients

73 lymph nodes (70 SLNs & 3 non-SLNs) from 41 cases with clinically localized cutaneous melanoma were studied prospectively under the IRB approved protocol. The demographics are shown in table 1. As this was as a research study, intraoperative decisions for the continuation of a regional lymphadenectomy were not executed regardless of positive results with immunostained imprint smear(s) of SLNs. This was explained to the patients participating in the study as a component of the informed consent.

All patients underwent mappings and biopsies of SLNs with a wide excision of the primary site at Froedert Memorial Lutheran Hospital/Medical College of Wisconsin, Milwaukee, WI. A standard surgical protocol was used to identify the SLN [37]. The tumor bed was injected preoperatively with technetium sulfur colloid. Additionally, dermis around the lesion was injected intraoperatively with isosulfan blue dye to facilitate the visual identification of the SLN [37]. The SLNs were harvested and submitted fresh without any fixative to pathology for intraoperative and permanent section evaluation.

Pathologic examination (Figure 1)

The excised lymph nodes were transected perpendicular to the long axis and processed to make imprint smears as previously reported [35]. The imprint smears were immunostained with the 'MCW melanoma cocktail' using either a manual method or the Dako® Autostainer with a rapid 17-minute immunostaining protocol utilizing the Dako Envision™+ System which does not contain avidin-biotin [35]. One smear of a previously prepared positive control from a known melanoma tumor and processed similar to test smears [35] was also immunostained with each staining batch.

The immunostained imprint smears were examined and interpreted as positive, indeterminate, or negative for melanoma metastases. The time required to go from preparation of imprint smears to evaluation of immunostained smears was also tracked. Based on the algorithm for intraoperative decision, indeterminate interpretations

Table 1: Demographics of all the cases.

Feature	Details
1 Number of case studied	Total- 41 case Males- 21, Females- 20 Mean age- 56 years (14 – 48 years)
2 Total lymph nodes studied	73 lymph nodes (SLN- 70, non-SLN- 3*) Mean- 1.7 SLN per case (1–4 SLN per case) 1 SLN- 16 cases 2 SLN- 17 cases 3 SLN- 4 cases 4 SLN- 4 cases
3 Pigmented lesions as indication for SLN biopsy	Melanomas- 39 Atypical Spitzoid nevus- 1 Dysplastic nevus- 1
4 Location of primary pigmented lesion	Head and neck (15), the trunk (11), the upper extremity (6), and the lower extremity (9).
5 Histological type of melanomas (known in 17 cases) ^{††}	Superficial spreading- 11 Nodular- 5 Superficial spreading with nodular- 1
6 Breslow thickness of primary melanoma (known in 38 patients)	Mean- 2.1 mm (range 0.7 to 8.9 mm)

*Case no. 23 (Table 2) had 5 lymph nodes (2 SLN and 3 non-SLN).

^{††}In most cases, the biopsy of primary lesion was performed and interpreted at outside institutions.

with immunostained imprint smears were considered as negative for statistical analysis.

After imprint smear preparation, the slices of SLNs were fixed in 10% formalin and processed in the usual manner for paraffin embedding. Three FPTS levels, each cut at 200-µm intervals were stained with hematoxylin and eosin (H&E). The levels adjacent to the middle H&E section were immunostained with 'MCW melanoma cocktail' using the avidin-biotin-peroxidase complex (ABC) method described previously [33].

The results were considered positive for melanoma metastases if cytoplasmic immunoreactivity was detected in cell clusters or individual cells that demonstrated morphologic features of melanoma tumor cells. When discrepancies existed between immunostained imprint smears and the immunostained FPTS, the slides were reviewed by another pathologist in an attempt to determine the cause of the discrepancy and to arrive at a conclusion (Table 2).

Results

The time required for completing the entire procedure from preparation of imprint smears to evaluation of

immunostained smears ranged from 24 to 45 (mean, 35) minutes and depended on the size-number of SLNs.

At the case level, melanoma metastases were identified in lymph nodes of 19.5% (8 out of 41) of patients by the immunohistochemical evaluation of FPTS. 87.5% (7 out of 8) of these cases showed metastases in imprint smears immunostained rapidly with the 'MCW melanoma cocktail', potentially saving a second surgery in all these cases. The test demonstrated a sensitivity of 89%, a specificity of 100%, the negative predictive value of 97%, and the positive predictive value of 100%.

At the lymph node level, 12% (9/73) nodes were positive for melanoma metastases with immunostained FPTS. Of these, 89% (8/9) showed melanoma metastases in intra-operatively immunostained imprint smears utilizing the cocktail demonstrating a sensitivity of 90%, a specificity of 100%, the negative predictive value of 99%, and the positive predictive value of 100%.

The immunostained tumor cells of melanoma metastases (Figure 2) showed a high nuclear to cytoplasmic ratio with non-granular cytoplasmic staining around the nuclei facilitating easy evaluation of nuclear details [35]. All 7 SLNs




Figure 1
 Pathological evaluation of sentinel lymph nodes for melanoma metastases. Section number 2, 5, & 8- stained with HE; 4- immunostained with 'MCW melanoma cocktail'; 6- negative control; 1, 3, 7, & 9- unstained sections on coated slides for immunostaining (but may be used for any stain). Number of slices of SLN shown (a,b,c) is for illustration only and would vary according to the size of the lymph node. (FPTS, formalin-fixed paraffin-embedded tissue sections; H&E, hematoxylin and eosin stain; immuno, immunohistochemistry)

from 7 cases with benign capsular melanocytic nevi showed negative results with the intraoperative evaluation of imprint smears.

An immunostained imprint smear was negative in one case with a small focus of melanoma metastases (4 small groups of 4–12 cells each in one small area) in one slice of a single SLN. 2 SLNs showed unequivocal melanoma

metastases in rapid immunostained imprint smear (Table 2, case 3 & 12). In these 2 SLNs, metastases were not detected by immunostained FPTS.

Two SLNs from 2 patients (Table 2, case 13 & 17) were interpreted as indeterminate. Both of these SLNs were negative for melanoma metastases by immunohistochemical evaluation of FPTS. In 2 other cases, rare, singly scat-

Table 2: Results with rapid intraoperative immunocytochemical evaluation of imprint smears.

Serial No.	No. of SLN per case	SLN		
		IC	SP	FR ⁴
1	2	B-,C-	B-cn,C-	N
2	1	A-	A-cn	N
3 [¶]	2	A1+,A2+,B-	A1+,A2-,B-	P
4	1	A-	A-cn	N
5	3	A-,B-,C-	A-,B-,C-	N
6	1	A-	A-	N
7	2	B-,C-	B-,C-	N
8	1	A-	A-	N
9	2	A-, C-	A-, C-	N
10	2	A-,C-	A-cn,C-	N
11*	4	A-,B-,C-,D-	A+,B-,C-,D-	P
12 [¶]	4	A-,B+,C+,D+	A-,B+,C+,D-	P
13 [†]	1	A(Intm)	A-	N
14	1	B+	B+	P
15	1	A-	A-	N
16	3	A+,B-,C-	A+,B-,C-	P
17 [†]	2	A(Intm) ,B-	A-,B-	N
18	1	A-	A-	N
19	2	A-,B-	A-,B-	N
20	2	A1-, C+	A1-, C+	P
21	1	A-	A-	N
22	2	A-,B-	A-,B-	N
23 ¹	1 ²	1A1-,1B+,1C-,D-,E-	1A1-,1B+,1C-,D-,E-	P
24	1	A-	A-	N
25	2	A-,B-	A-,B-	N
26	2	A-,C-	A-,C-	N
27	1	B-	B-cn	N
28	1	A-	A-	N
29	1	A-	A-cn	N
30	1	A-	A-	N
31 ²	4	A-,B-,C-,D-	A-,B-,C-,D-	N
32	2	A-,B-	A-,B-	N
33	1	A-	A-	N
34	4	A-,B-,C-,D-	A-,B-,C-,D-	N
35	3	A-,B-,C-	A-,B-,C-	N
36 ³	1	A-	A-	N
37	2	A-	A-	N
38	2	B-,C-	B-,C-	N
39	2	A-,B-	A-,B-	N
40	3	A-,B-,D-	A-,B-,D-	N
41	2	A-,B+	A-,B+	P

*One false negative

[†]Two negative cases showed indeterminate results with IC

[¶]Two SLN were positive unequivocally with IC but negative by SP

¹Only D&E were submitted as sentinel LN (A,B,C were submitted as non-SLN);

²Atypical Spitzoid nevus, recommended SLN biopsy;

³Dysplastic nevus, recommended SLN biopsy;

⁴Final results summarizing findings in all SLN in a particular case after immunostaining of permanent sections: total number of positive cases- 8 and negative cases- 33.

Abbreviations in alphabetical order: +, positive for melanoma metastases; -, negative for melanoma metastases; **cn**, capsular nevus; FR, final result; IC, rapid intraoperative immunocytochemistry; **Intm**, indeterminate for melanoma metastases; LN, sentinel and non-sentinel lymph nodes; N, negative; **P**, positive; SP, final result on permanent sections.

tered cells with benign morphology but with cytoplasmic immunostaining with the cocktail were observed in both immunostained imprint smears and permanent sections.

Discussion

In the current study, 8 out of 41 patients showed melanoma metastases in lymph nodes employing immu-




Figure 2
 Cytomorphological spectrum of tumor cells (arrows) of melanoma metastases immunostained with 'MCW melanoma cocktail'. The tumor cells were larger and showed high N/C ratio with non-granular cytoplasmic staining around the nuclei with usually clear nuclear details. The nuclear chromatin did not simulate the chromatin of lymphocytes in the background. The nucleoli may be prominent. The cell margins were well defined. (HE-FPTS, Hematoxylin-eosin stained formalin-fixed paraffin-embedded tissue sections; ICIS, immunocytochemical evaluation of imprint smears).

nohistochemical evaluation of FPTS. 7 out of these 8 cases showed metastases on imprint smears immunostained with the 'MCW melanoma cocktail', potentially avoiding a second surgery at a later date in 87.5% of these patients.

On a case basis, rapid intraoperative evaluation of imprint smears with the 'MCW melanoma cocktail' yielded a sensitivity of 89% and a specificity of 100%. On a lymph node basis, sensitivity was 90% and specificity was 100% (Table 2). These encouraging results are more promising than alternative intraoperative approaches such as the frozen-section alone [27], immunostaining frozen sections with a cocktail of Melan-A, HMB-45, & tyrosinase [32], or a morphological evaluation of imprint smears alone [30,38] (Table 3).

Finding a positive SLN and completing the regional lymphadenectomy under the same anesthesia offers many

advantages. The extra cost for the second procedure was predominantly the hospital cost. In this series with 41 patients, the extra cost (after deducting the cost for the regional lymph node dissection procedure and adding the cost for extended anesthesia) for 8 regional lymph node dissections that needed to be performed at a later date was \$ 60,000 (average \$ 7,500 per case). In comparison, the cost of the intraoperative immunocytochemical evaluation for 70 SLNs in all 41 cases ([CPT codes 88329 (for intraoperative consult) + 88161 (for preparation and processing of imprint smears for immunostaining) + 88342 (immunostaining and interpretation of immunostained smears)] X 70) was only \$33,233, resulting in nearly 50% cost saving.

The most important benefit that cannot be quantified easily is the total avoidance of potential morbidity and mortality associated with an additional surgery at a later date,

Table 3: Comparison of studies evaluating melanoma SLNs intraoperatively

Authors	Intraoperative evaluation	Sensitivity (%)	Specificity (%)
Gibbs et al [20A]	FS	43	100
Clary et al [20B]	FS	56	100
Tanis et al [20C]	FS	47	100
Stojadinovic [20]	FS	59	100
Creager et al [21]	IS	38	100
Eudy et al [23]	FS with IHC	86	97
Current study	ICIS	90	100

FPTS, formalin-fixed paraffin-embedded tissue section; FS, frozen section, ICIS, immunocytochemical evaluation of imprint smears with 'MCW melanoma cocktail' (mixture of Melan- A, MART- 1, & tyrosinase); IHC, immunohistochemistry with cocktail of Melan- A, HMB-45, & tyrosinase); IS, imprint smear; SLNs, sentinel lymph nodes; MM, melanoma metastases.

improving patient care. Additionally, saving the patient from a second visit to the surgical suite and its substantial attendant costs along with a decreased number of office visits (to reschedule the regional lymphadenectomy), lessens the inconvenience for the patient.

In cases with positive intraoperative SLN results, the duration of the surgical procedure would be lengthened for the completion of the regional lymphadenectomy. Though it demands flexibility in surgical scheduling, it may be worth at most institutions.

As observed in one case, immunostained imprint smears of SLN that turn out negative may be followed by positive results after immunostaining the FPTS. This may require the patient to return to the surgical suite for a lymphadenectomy at a later date. The patients should be made aware of this possibility during preoperative consultations.

Due to sampling benefits associated with imprint smears [35], the immunostaining of imprint smears identified metastases that may have been missed by studying immunostained FPTS alone. This was observed in 2 cases in which immunostained imprint smears of 2 SLNs were unequivocally positive for melanoma metastases, but immunostained FPTS were negative (Table 2, case 3 & 12). Additional SLNs submitted in these 2 patients were positive with both immunostained imprint smears and FPTS, further endorsing the true positive nature of finding.

One SLN from another case showed a micro-focus of melanoma metastases in a single slice in immunostained FPTS. However, the cells from this micro-focus with very few tumor cells were not sampled by the imprint smears leading to a false negative result. This underscores the significance of chance factor associated with sampling in general during the evaluation of SLN by any method. Unequivocal positive result, obtained with either immunostained imprint smears or with immunostained FPTS, are significant. In cases where the intraoperative results

are positive, SLNs need not be evaluated further by immunohistochemistry on FPTS. However, if the intraoperative result is negative, immunohistochemical evaluation of SLNs should go forward on FPTS. This would enhance the sampling and increase the chances of detecting additional melanoma metastases [35].

As a significant advantage, the cells of capsular nevi in 7 SLNs from 7 cases located in lymph node capsule and/or septa as collections of spindle cells, did not exfoliate and adhere to slides during the preparation of imprint smears. As discussed previously, this is related to the cohesive nature of benign nevus cells in capsular melanocytic nevi, which would not exfoliate cells to the glass slide in contrast to poorly cohesive melanoma cells [33,35]. This result is a distinct advantage for the immunocytochemical evaluation of imprint smears over other methods such as RT-PCR, which may not have the benefit of a morphological correlation to avoid false positive results with benign melanocytic capsular nevi (24).

Two SLNs from 2 patients, negative for melanoma metastases by immunohistochemical evaluation of FPTS, were interpreted as indeterminate in immunostained imprint smears (Table 2 case 13 & 17). Retrospectively, the rare doubtful cells observed in immunostained imprint smears were consistent with mast cells which demonstrated brown staining (even in respective negative controls) due to endogenous peroxidase activity which could not be blocked during the brief endogenous peroxidase blocking step required by the rapid protocol [35]. Familiarity with morphological spectrum of immunostained tumor cells (Figure 1) and other non-specifically stained structures including mast cells in imprint smears prevents indeterminate interpretation [35]. In two other cases, singly scattered cells showing cytoplasmic immunostaining accompanied by small and inconspicuous nuclei were observed. These rare single cells were also present in immunostained permanent sections. The cytomorphology was consistent with a benign interpretation in both immunostained imprint smears and the permanent sec-

tions. Similar rare cells with benign morphology have been reported in SLNs evaluated with MART-1 and Melan-A [39].

For various reasons every laboratory may not be comfortable using cytological methods. However, objective nature of interpreting immunostained tumor cells in imprint smears would allow interpretation by most of the pathology laboratories after a minor learning curve [35].

Imprint smears are less expensive and faster than frozen sectioning without cryostat related tissue loss. They avoid the frequently observed problems associated with the frozen sectioning of fatty lymph nodes. If imprint smears are made and the tissue is not frozen, it would prevent the introduction of freezing artifacts and the associated interpretation challenges on the permanent sections of such frozen tissue.

Other approaches for the intraoperative evaluation of SLN have demonstrated lower sensitivities (Table 3) but had 100% specificity, which is extremely important in order to avoid un-indicated regional lymph-adenectomies [26-32]. One study evaluating immunostaining of frozen sections demonstrated a slightly increased sensitivity than when imprint smears or frozen sections alone were used without immunostaining. However, the specificity was less than 100% (Table 3). The immunostained frozen sections may show significant artifacts along with folds, background staining, missing areas, and poor morphology. As HMB45 is known to stain non-melanoma cells in SLN [33,40-42], incorporation of HMB45 in the cocktail used in this study may have contributed further to a reduction in the specificity [32,41,42]. As stated by the reporting authors of the study, a recent consensus group has discouraged frozen-section examination of SLN [32].

In summary, imprint smears, rapidly immunostained with the 'MCW melanoma cocktail' is a sensitive and specific method for the rapid intraoperative evaluation of SLNs. If a SLN is found to be positive for melanoma metastases in this way, the completion of a regional lymphadenectomy during the same surgical procedure for SLN biopsy is feasible. Both negative and indeterminate results should be regarded as negative when considering intraoperative decision making for a regional lymph node dissection during a given surgical procedure. In such cases, the final decision for a regional lymph node dissection should be deferred until the final results with FPTS are available.

Abbreviations

FPTS, formalin-fixed paraffin-embedded tissue section; H&E, hematoxylin and eosin; SLN, sentinel lymph node;

Acknowledgements

Part of this study was supported by the Cancer Center Research Multidisciplinary Grant from Medical College of Wisconsin, Milwaukee, WI and in part by Armour family grant through Chicago Marathon.

Authors thank Virgilia Macias, MD; Sushma Kaul, MS; Glen Dawson, BS, HT, QIHC (ASCP); Aurora Kallenbach, HT (ASCP); and Jerome Jacobson, HT, QIHC (ASCP) for their expert technical assistance in immunochemistry. We also thank Christine M. Santiago, Compliance Education Coordinator at MCW for reviewing the cost and CPT code related comments.

References

- Landis SH, Murray T, Bolden S, Wingo PA: **Cancer statistics, 1999.** *CA Cancer J Clin* 1999, **49**:8-31,1.
- Medalie NS, Ackerman AB: **Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: an assertion based on comprehensive, critical analysis: part I.** *Am J Dermatopathol* 2003, **25**:399-417.
- Medalie NS, Ackerman AB: **Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: an assertion based on comprehensive, critical analysis: part II.** *Am J Dermatopathol* 2003, **25**:473-84.
- Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Ross MI, Jewell WR, Mihm MC, Barnhill RL, Wanebo HJ: **Efficacy of an elective regional lymph node dissection of I to 4 mm thick melanomas for patients 60 years of age and younger.** *Ann Surg* 1996, **224**:255-63. discussion 263-6.
- Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F: **Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial.** *WHO Melanoma Programme Lancet* 1998, **351(9105)**:793-6.
- Salti GI, Das Gupta TK: **Predicting residual lymph node basin disease in melanoma patients with sentinel lymph node metastases.** *Am J Surg* 2003, **186**:98-101.
- Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W: **Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes – one institution's experience.** *Melanoma Res* 2003, **13**:35-43.
- Manca G, Facchetti F, Pizzocaro C, Biasca F, Farfaglia R, Simoncini E, Cristinelli MR, Flocchini M, Parrinello G, Manganoni A: **Nodal staging in localized melanoma. The experience of the Brescia Melanoma Unit.** *Br J Plast Surg* 2003, **56**:534-9.
- Rutkowski P, Nowecki ZI, Nasierowska-Guttmejer A, Ruka W: **Lymph node status and survival in cutaneous malignant melanoma – sentinel lymph node biopsy impact.** *Eur J Surg Oncol* 2003, **29**:611-8.
- Wagner JD, Ranieri J, Evdokimow DZ, Logan T, Chuang TY, Johnson CS, Jung SH, Wenck S, Coleman JJ 3rd: **Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.** *Plast Reconstr Surg* 2003, **112**:486-97.
- Zapas JL, Coley HC, Beam SL, Brown SD, Jablonski KA, Elias EG: **The risk of regional lymph node metastases in patients with melanoma less than 1.0 mm thick: recommendations for sentinel lymph node biopsy.** *J Am Coll Surg* 2003, **197**:403-7.
- Gad D, Sjogren P: **[Sentinel lymph node biopsy in patients with cutaneous malignant melanoma].** *Ugeskr Laeger* 2003, **165**:2567-70. Danish.
- Kaikaris V, Valiukeviciene S, Rimdeika R, Gollnick H, Ulrich J: **[Sentinel lymph node biopsy in melanoma patients: methods, indications, and clinical significance].** *Medicina (Kaunas)* 2003, **39**:621-30. Review. Lithuanian.
- Arens A, Osinga J, Schwipper V, Schober O, Tilkorn H, Liebau J: **[Sentinel lymph node dissection in patients with malignant melanoma. Diagnostic and therapeutic standards].** *Chirurg* 2003, **74**:665-70. German.
- Santinami M, Baldi M, Tragni G, Maurichi A, Moglia D, Bono A, Bartoli C, Patuzzo R, Pennacchioli E, Cascinelli N: **[Impact of sentinel lymph node biopsy on the treatment of melanoma].** *Tumori* 2003, **89(4 Suppl)**:273-5. Italian.
- Al-Hiari AA, Al-Kaylani H: **Sentinel node in management of malignant melanoma.** *Saudi Med J* 2002, **23**:1462-5.

17. Pu LL, Wells KE, Cruse CW, Shons AR, Reintgen DS: **Prevalence of additional positive lymph nodes in complete lymphadenectomy specimens after positive sentinel lymphadenectomy findings for early-stage melanoma of the head and neck.** *Plast Reconstr Surg* 2003, **112**:43-9.
18. Buonomo O, Felici A, Granai AV, Piccirillo R, De Liguori Carino N, Guadagni F, Mariotti S, Orlandi A, Tipladi G, Cipriani C, Chimenti S, Cervelli V, Casciani CU, Roselli M: **Sentinel lymphadenectomy in cutaneous melanoma.** *Tumori* 2002, **88**:S49-51.
19. Nieweg OE, Eggermont AM, Kroon BB: **[Sentinel node biopsy in melanoma: some critical questions].** *Ned Tijdschr Geneesk* 2002, **146**:1774-7. Review. Dutch
20. Essner R, Cochran AJ: **Sentinel node biopsy: not only a staging tool?** *Recent Results Cancer Res* 2002, **160**:133-48.
21. Thompson JF: **The Sydney Melanoma Unit experience of sentinel lymphadenectomy for melanoma.** *Ann Surg Oncol* 2001, **8(9 Suppl)**:44S-47S.
22. Cascinelli N, Belli F, Santinami M, Fait V, Testori A, Ruka W, Cavaliere R, Mozzillo N, Rossi CR, MacKie RM, Nieweg O, Pace M, Kirov K: **Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience.** *Ann Surg Oncol* 2000, **7**:469-74.
23. Havenga K, Cobben DC, Oyen WJ, Nienhuijs S, Hoekstra HJ, Ruers TJ, Wobbes T: **Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma.** *Eur J Surg Oncol* 2003, **29**:662-4.
24. Schafer A, Herbst RA, Beiteke U, Lange-Ionescu S, Treckmann H, Lohlein D, Thiemann G, Theophil B, Schwarze EW, Bartels HJ, Frosch PJ: **[Sentinel lymph node excision (SLNE) and positron emission tomography in the staging of stage I-II melanoma patients].** *Hautarzt* 2003, **54**:440-7. German.
25. Stojadinovic A, Allen PJ, Clary BM, Busam KJ, Coit DG: **Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma.** *Ann Surg* 2002, **235**:92-8.
26. Gibbs JF, Huang PP, Zhang PJ, Kraybill WG, Cheney R: **Accuracy of pathologic techniques for the diagnosis of metastatic melanoma in sentinel lymph nodes.** *Ann Surg Oncol* 1999, **6**:699-704.
27. Clary BM, Lewis JJ, Brady MS, Busam K, Coit DG: **Should frozen section analysis of the sentinel node be performed in patients with melanoma?** *Eur J Nucl Med* 1999, **26**:S68.
28. Tanis PJ, Boom RP, Koops HS, Faneyte IF, Peterse JL, Nieweg OE, Rutgers EJ, Tiebosch AT, Kroon BB: **Frozen section investigation of the sentinel node in malignant melanoma and breast cancer.** *Ann Surg Oncol* 2001, **8**:222-26.
29. Creager AJ, Shiver SA, Shen P, Geisinger KR, Levine EA: **Intraoperative evaluation of sentinel lymph nodes for metastatic melanoma by imprint cytology.** *Cancer* 2002, **94**:3016-22.
30. Hocevat M, Bracko M, Pogacnik A, Videgar-Kralj B, Besic N, Zgajnar J: **Role of imprint cytology in the intraoperative evaluation of sentinel lymph nodes for malignant melanoma.** *Eur J Cancer* 2003, **39**:2173-8.
31. Eudy GE, Carlson GW, Murray DR, Waldrop SM, Lawson D, Cohen C: **Rapid immunohistochemistry of sentinel lymph nodes for metastatic melanoma.** *Hum Pathol* 2003, **34**:797-802.
32. Shidham VB, Qi D, Rao RN, Acker SM, Chang CC, Kampalath B, Dawson G, Machhi JK, Komorowski RA: **Improved Immunohistochemical Evaluation of Micrometastases in Sentinel Lymph Nodes of Cutaneous Melanoma with MCW Melanoma Cocktail - A Mixture of Monoclonal Antibodies to MART-1, Melan-A, and Tyrosinase.** *BMC Cancer* 3(1p1-9 [<http://www.biomedcentral.com/qc/1471-2407/3/15>]. 2003 May 7;[PubMed PMID: 12735792]
33. Shidham VB, Komorowski R: **'MCW melanoma cocktail' for evaluation of metastases in sentinel lymph nodes of cutaneous melanoma.** *Expert Review of Molecular Diagnostics* 2005, **5(3)**:281-290.
34. Shidham V, Macias V, Neuberger M, Chavan A, Rao RN, Basir Z, Walker A, Dzwierzynski WW: **Rapid intraoperative immunocytochemical evaluation of cutaneous melanoma sentinel lymph nodes for melanoma metastases with 'MCW Melanoma Cocktail'.** *Acta Cytol* 2003, **47**:938.
35. Shidham VB, Komorowski R, Dawson G, Kaul S, Chang CC, Macias V: **Optimization of immunostaining protocol for rapid intraoperative evaluation of imprint smears of melanoma sentinel lymph nodes with 'MCW melanoma cocktail'.** *Cytojournal* 2004, **1:2** [<http://www.cytojournal.com/content/1/1/2>]. doi:10.1186/1742-6413-1-2
36. Spanknebel K, Coit DG, Bielick SC, Gonen M, Rosai J, Klimstra DS: **Characterization of Micrometastatic Disease in Melanoma Sentinel Lymph Nodes by Enhanced Pathology: Recommendations for Standardizing Pathologic Analysis.** *Am J Surg Pathol* 2005, **29**:305-17.
37. Kapteijn BA, Nieweg OE, Liem I, Mooi WJ, Balm AJ, Muller SH, Peterse JL, Valdes Olmos RA, Hoefnagel CA, Kroon BB: **Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye.** *Ann Surg Oncol* 1997, **4**:156-60.
38. Messina JL, Glass LF, Cruse CW, Berman C, Ku NN, Reintgen DS: **Pathologic examination of the sentinel lymph node in malignant melanoma.** *Am J Surg Pathol* 1999, **23**:686-90.
39. Yan S, Brennick JB: **False-positive rate of the immunoperoxidase stains for MART1/MelanA in lymph nodes.** *Am J Surg Pathol* 2004, **28**:596-600.
40. Mahmood MN, Lee MW, Linden MD, Nathanson SD, Hornyak TJ, Zarbo RJ: **Diagnostic Value of HMB-45 and Anti-Melan A Staining of Sentinel Lymph Nodes with Isolated Positive Cells.** *Mod Pathol* 2002, **15**:1288-93.
41. Shidham VB, Susnik B, Rao RN, Chivukula M, Kampalath B, Komorowski R: **HMB45 immunoreactive single cells in sentinel lymph nodes negative for melanoma micrometastases are mast cells.** *Mod Pathol* 2004, **17(Supplement 1)**:1a-388a.
42. Shidham VB, Qi DY, Acker S, Kampalath B, Chang CC, George V, Komorowski R: **Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: Higher diagnostic accuracy with Melan-A and MART-I compared to S-100 protein and HMB-45.** *Am J Surg Pathol* 2001, **25**:1039-46.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

